Etavopivat is an investigational new drug that is being evaluated by FORMA Therapeutics for the treatment of sickle cell disease and thalassemia. It is an allosteric activator of the erythrocyte pyruvate kinase R (PKR) enzyme.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.